Anaplastic large cell lymphoma (ALCL), specifically anaplastic lymphoma kinase (ALK)-positive ALCL, is a rare and aggressive type of non-Hodgkin’s lymphoma (NHL), that accounts for 10-20% of pediatric NHL and 1-3% of adult NHL with high risk of relapse. ALK-positive ALCL is characterized by high CD30 and abnormal ALK protein expression. Currently available therapies for ALK-positive ALCL are mainly based on chemotherapy, that suffers from variable efficacy, significant side effects, and poor selectivity. Several ALK inhibitors have been proposed to treat this disease, but the emergence of drug resistance has limited their clinical application. Therefore, the development of novel therapeutic strategies is essential to improve the overall clinical outcomes for ALK-positive ALCL.